GT Biopharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of GT Biopharma generated cash of -$8,852,000, which is more than the previous year. Cash used in financing activities reached the amount of $6,268,000 last year. Net change in cash is therefore -$4,593,000.
Cash Flow
| 2014 | -1.74M | -6K | 2.58M |
|---|---|---|---|
| 2015 | -4.65M | -1K | 3.85M |
| 2016 | -1.93M | -1K | 1.90M |
| 2017 | -5.43M | -4K | 5.99M |
| 2018 | -10.67M | -36K | 10.19M |
| 2019 | -3.65M | 200K | 3.42M |
| 2020 | -7.26M | 0 | 12.53M |
| 2021 | -15.60M | -23.04M | 42.31M |
| 2022 | -15.21M | 12.14M | -224K |
| 2023 | -8.85M | -2.00M | 6.26M |
GTBP Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 5.67M | 8.96M | 5.29M | 28K | 60K | 576K | 19K | 47K | 855K | 43K |
Operating activities | ||||||||||
Net income | -7.59M | -20.88M | -58.01M | -28.29M | -38.64M | -259.18M | -143.24M | 21.03M | -32.72M | -23.48M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 0 | 0 | 317K | 4K | 7K | 2K | 1K | 2K | 22K |
Stock-based compensation expense | 2.2M | 7.64M | 33.92M | 269K | 5.30M | 0 | 130.12M | 6.59M | 3.76M | 2.63M |
| Deferred income tax benefit | 2.2M | 7.64M | 33.92M | 269K | 5.30M | 0 | 130.12M | 6.59M | 3.76M | 2.63M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.11M | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 42K | 42K |
Accounts payable | 1.96M | -2.03M | 7.07M | -838K | 3.15M | 136K | 1.41M | 880K | -276K | -276K |
Cash generated by operating activities | -8.85M | -15.21M | -15.60M | -7.26M | -3.65M | -10.67M | -5.43M | -1.93M | -4.65M | -1.74M |
Investing activities | ||||||||||
Purchases Of Investments | -2.00M | 12.14M | -23.04M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | -36K | -4K | 0 | -1K | -6K |
Acquisitions Net | 0 | 0 | 0 | 0 | 200K | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -2.00M | 12.14M | -23.04M | 0 | 200K | -36K | -4K | -1K | -1K | -6K |
Financing activities | ||||||||||
Common Stock Issued | 6.26M | 0 | 41.11M | 1.74M | 1.36M | 325K | 0 | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -224K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -1.20M | -12.53M | 0 | -4.41M | 5.99M | -1.90M | 3.85M | -6K |
Cash used in financing activities | 6.26M | -224K | 42.31M | 12.53M | 3.42M | 10.19M | 5.99M | 1.90M | 3.85M | 2.58M |
Net Change In Cash | -4.59M | -3.29M | 3.67M | 5.26M | -32K | -516K | 557K | -28K | -808K | 812K |
Cash at end of period | 1.07M | 5.67M | 8.96M | 5.29M | 28K | 60K | 576K | 19K | 47K | 855K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |